- New Daily GLP-1 Weight Loss Pill Aims to Take on Ozempic Everyday Health
- Lilly’s oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial Eli Lilly and Company
- What to Know About Eli Lilly’s Daily Pill for Weight Loss The New York Times
- A very good day for Lilly, and a bad day for Novo statnews.com
- Lilly’s obesity pill scores in large diabetes trial BioPharma Dive